mcnicoll lewis vlak

McNicoll Lewis Vlak initiated coverage on Coronado Biosciences (NASDAQ: CNDO) with a Buy rating and a $10 price target. McNicoll Lewis Vlak noted, "We are initiating coverage on Coronado Biosciences, Inc., with a BUY recommendation and $10.00 price target, as we view Coronado's innovative...

McNicoll Lewis Vlak initiated coverage on Galena Biopharma (NASDAQ: GALE) with a Buy rating and a $6 price target. McNicoll Lewis Vlak commented, "As we near the end of Breast Cancer Awareness month, we are initiating coverage on Galena Biopharma Inc. with a BUY recommendation and one-year price...

McNicoll Lewis Vlak has published a research report on Spectrum Pharmaceuticals (NASDAQ: SPPI) after the company reported positive results from Zevalin in the Journal 'Cancer'. In the report, MLV writes, "In several studies, we think Zevalin is beginning to demonstrate its potential for wide...

McNicoll Lewis Vlak has initiated coverage on Avanir Pharmaceuticals (NASDAQ: AVNR) with a Buy rating and $6 price target.

McNicoll Lewis Vlak has lowered the price target on AMAG Pharmaceuticals (NASDAQ: AMAG) from $23 to $21 and maintains its Buy rating.

McNicoll Lewis & Vlak has downgraded Inhibitex (NASDAQ: INHX) from Buy to Hold with a $26 price target.

McNicoll Lewis & Vlak has initiated coverage on Zalicus (NASDAQ: ZLCS) with a Buy rating and $4 price target.

McNicoll Lewis & Vlak has initiated coverage on DexCom (NASDAQ: DXCM) with a Buy rating and $11 price target.

McNicoll Lewis & Vlak has downgraded BioSante Pharmaceuticals (NASDAQ: BPAX) from Buy to Hold.

McNicoll Lewis & Vlak has raised the price target on AMAG Pharmaceuticals (NASDAQ: AMAG) to $23 and maintains its Buy rating.

MLV & Co maintains its Buy rating and $10 target price on Synta Pharmaceuticals Corp. (NASDAQ: SNTA) as the company announces results of a Phase II trial of its lead dug candidate. MLV notes, “We are maintaining our one-year target price of $10.00 and BUY recommendation for Synta...

A report from MLV & Co reiterates its Buy rating and $21 price target on Transcept Pharmaceuticals (NASDAQ: TSPT). The report states, “With an approved product, royalties that range from mid-teens to 40%, a multi-billion dollar market, and a skilled partner with deep pockets, we view TSPT (...

A report from MLV & Co reiterates its Buy rating and $15 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY). The report states, “ALNY recently reported positive top-line data from its Phase I study with ALN-TTR01 for the treatment of TTR-mediated amyloidosis (ATTR). ALN-TTR01 demonstrated...

A report from MLV & Co reiterates its Buy rating and $10 price target on Synta Pharmaceuticals (NASDAQ: SNTA). The report states, “In 3Q:11, Synta commenced a key randomized but open label Phase IIb trial of ganetespib in combination with Taxotere in patients with Stage IIIB and IV nonsmall...

A report from MLV & Co reiterates its Buy rating and lowers its price target to $4 on TranS1 (NASDAQ: TSON). The report states, “TranS1 was denied a Category I CPT code at the American Medical Association October 2011 CPT Editorial Panel meeting. The Company plans to appeal the decision....